The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide

• Verfasst von: Schmitt, Stefan [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Titel: The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide
• Verf.angabe: Stefan Schmitt, Anthony D. Ho, Hartmut Goldschmidt
• E-Jahr: 2010
• Jahr: March 19 2010
• Umfang: 4 S.
• Fussnoten: Gesehen am 14.06.2023
• Titel Quelle: Enthalten in: Onkologie
• Ort Quelle: Basel : Karger, 1978
• Jahr Quelle: 2010
• Band/Heft Quelle: 33(2010), 4 vom: Apr., Seite 183-186
• ISSN Quelle: 1423-0240
• DOI: doi:10.1159/000286447
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1848968736

Abstract

Multiple myeloma as the second most common hematological malignancy is characterized by proliferation of monoclonal plasma cells. This entity still remains a non-curable disorder leading, amongst others, to complications as myeloma bone disease, bleeding events, kidney failure and neurological impairment. LBH589 is a histone deacetylase inhibitor with an epigenetic mechanism of action and the potential for treatment in myeloma. We report here about the successful treatment of a 44-year-old woman suffering from progressive myeloma with LBH589 after five different chemotherapies. During the 9 years after first diagnosis of myeloma in April 2000, our patient twice underwent an autologous stem cell transplantation and was also treated with the new substances bortezomib, thalidomide and lenalidomide.